Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia

An overview of lefamulin for the treatment of community acquired bacterial pneumonia

(2020) Vicenç Falcó et al.   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial

(2019) Thomas M File et al.   CLINICAL INFECTIOUS DISEASES

Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015–2016 and Characterization of Resistance Mechanisms

(2019) Rodrigo E. Mendes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015–2016)

(2019) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing

(2019) Wolfgang W Wicha et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods

(2019) Li Zhang et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia

(2019) Sujata M Bhavnani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae

(2019) Wolfgang W Wicha et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model

(2019) Wolfgang W Wicha et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Therapeutic potential of lefamulin in the treatment of community acquired pneumonia

(2019) Whitney Perry et al.   Future Microbiology

Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia

(2019) Elizabeth Alexander et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia

(2019) Young Ran Lee et al.   DRUGS

722. Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Hepatic Function

(2019) Wolfgang Wicha et al.   Open Forum Infectious Diseases

705. Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Renal Function and in Those Requiring Hemodialysis

(2019) Wolfgang Wicha et al.   Open Forum Infectious Diseases

703. In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2017–2018 Results From the United States (US)

(2019) Helio S Sader et al.   Open Forum Infectious Diseases

In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens

(2018) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Lefamulin: Review of a promising novel pleuromutilin antibiotic

(2018) Michael P. Veve et al.   PHARMACOTHERAPY

Lefamulin: a promising new pleuromutilin antibiotic in the pipeline

(2018) Caroline Dillon et al.   Expert Review of Anti-Infective Therapy

1353. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP): 2016 SENTRY Data From the United States

(2018) Susanne Paukner et al.   Open Forum Infectious Diseases

1365. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2016 Results From Asia-Pacific (APAC) and Latin America (LA)

(2018) Susanne Paukner et al.   Open Forum Infectious Diseases

2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study

(2018) Thomas File et al.   Open Forum Infectious Diseases

New Horizons in Mycoplasma genitalium Treatment

(2017) Catriona S Bradshaw et al.   JOURNAL OF INFECTIOUS DISEASES

Synthesis and Biological Activity Evaluation of Novel Heterocyclic Pleuromutilin Derivatives

(2017) et al.   MOLECULES

In Vitro Activity of Lefamulin against S. aureus Collected Worldwide from Hospitalized Patients with Bacterial Pneumonia

(2017) Susanne Paukner et al.   Open Forum Infectious Diseases

Efficacy of Lefamulin Against Staphylococcus aureus-Induced Bacteremia in a Neutropenic and Immunocompetent Murine Model

(2017) Evelin Fischer et al.   Open Forum Infectious Diseases

In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015)

(2017) Susanne Paukner et al.   Open Forum Infectious Diseases

In Vitro Activity of Lefamulin and Other Antimicrobial Agents Against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China

(2016) Ken B. Waites et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States

(2016) Rodrigo E. Mendes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid

(2016) M. Zeitlinger et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pleuromutilins: Potent Drugs for Resistant Bugs—Mode of Action and Resistance

(2016) Susanne Paukner et al.   Cold Spring Harbor Perspectives in Medicine

A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism

(2016) Zohar Eyal et al.   Scientific Reports

Structural insights into species-specific features of the ribosome from the pathogenStaphylococcus aureus

(2015) Zohar Eyal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Population Pharmacokinetic Analyses for BC-3781 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections

(2014) C. M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase II Clinical Study of BC-3781, a Pleuromutilin Antibiotic, in Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections

(2013) W. T. Prince et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010

(2013) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of the Investigational Pleuromutilin Compound BC-3781 Tested against Gram-Positive Organisms Commonly Associated with Acute Bacterial Skin and Skin Structure Infections

(2012) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel pleuromutilin derivatives as antibacterial agents: Synthesis, biological evaluation and molecular docking studies

(2012) Xinyang Wang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)

(2012) H. S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Are pleuromutilin antibiotics finally fit for human use?

(2011) Rodger Novak   Annals of the New York Academy of Sciences

Ceftobiprole

(2009) George G Zhanel et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY